Suboptimal outcomes in patients with PKU treated early with diet alone: Revisiting the evidence

Molecular Genetics and Metabolism

Volumn 101, Issue 2-3, 2010, Pages 99-109

  Enns, G M ^a   Koch, R ^b   Brumm, V ^a   Blakely, E ^c   Suter, R ^d   Jurecki, E ^d  

^a LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d BIOMARIN PHARMACEUTICAL INC   (United States)

Author keywords

Diet; NIH Consensus Statement; Outcomes; Phenylketonuria; Recommendations; Suboptimal

Indexed keywords

BONE DISEASE; BRAIN DISEASE; COGNITION; CONSENSUS; DIET THERAPY; HUMAN; NATIONAL HEALTH ORGANIZATION; NUTRITION; OUTCOME ASSESSMENT; PHENYLKETONURIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCREENING; SOCIAL PSYCHOLOGY; STANDARDIZATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VALIDITY;

ADOLESCENT; ADULT; BONE AND BONES; BONE DENSITY; BRAIN; CHILD; CHILD, PRESCHOOL; COGNITION DISORDERS; CONSENSUS DEVELOPMENT CONFERENCES, NIH AS TOPIC; FEMALE; HUMANS; INFANT, NEWBORN; META-ANALYSIS AS TOPIC; MOTHERS; NEONATAL SCREENING; PHENYLALANINE; PHENYLKETONURIAS; PREGNANCY; PREGNANCY COMPLICATIONS; QUALITY OF LIFE; TREATMENT OUTCOME; UNITED STATES;

SCOPUS;

EID: 77957237994     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2010.05.017     Document Type: Review

References (182)

1. Scriver C.R., Kaufman S. Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. The Metabolic and Molecular Bases of Inherited Disease 2001, McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, D. Valle, W.S. Sly (Eds.).
2. National Institutes of Health Consensus Development Conference Statement. Phenylketonuria (PKU): Screening and Management, October 16-18, 2000. Pediatrics 2001, 108:972-982. National Institutes of Health Consensus Development Panel.
3. NIH Consensus Development Program http://consensus.nih.gov/.
4. Agostoni C., Verduci E., Massetto N., Radaelli G., Riva E., Giovannini M. Plasma long-chain polyunsaturated fatty acids and neurodevelopment through the first 12 months of life in phenylketonuria. Dev. Med. Child Neurol. 2003, 45:257-261.
5. Albrecht J., Garbade S.F., Burgard P. Neuropsychological speed tests and blood phenylalanine levels in patients with phenylketonuria: a meta-analysis. Neurosci. Biobehav. Rev. 2009, 33:414-421.
6. Anastasoaie V., Kurzius L., Forbes P., Waisbren S. Stability of blood phenylalanine levels and IQ in children with phenylketonuria. Mol. Genet. Metab. 2008, 95:17-20.
7. Anderson P.J., Wood S.J., Francis D.E., Coleman L., Warwick L., Casanelia S., Anderson V.A., Boneh A. Neuropsychological functioning in children with early-treated phenylketonuria: impact of white matter abnormalities. Dev. Med. Child Neurol. 2004, 46:230-238.
8. Anderson P.J., Wood S.J., Francis D.E., Coleman L., Anderson V., Boneh A. Are neuropsychological impairments in children with early-treated phenylketonuria (PKU) related to white matter abnormalities or elevated phenylalanine levels?. Dev. Neuropsychol. 2007, 32:645-668.
9. Araujo G.C., Christ S.E., Steiner R.D., Grange D.K., Nardos B., McKinstry R.C., White D.A. Response monitoring in children with phenylketonuria. Neuropsychology 2009, 23:130-134.
10. Arnold G.L., Vladutiu C.J., Orlowski C.C., Blakely E.M., DeLuca J. Prevalence of stimulant use for attentional dysfunction in children with phenylketonuria. J. Inherit. Metab. Dis. 2004, 27:137-143.
11. Baieli S., Pavone L., Meli C., Fiumara A., Coleman M. Autism and phenylketonuria. J. Autism Dev. Disord. 2003, 33:201-204.
12. Banich M.T., Passarotti A.M., White D.A., Nortz M.J., Steiner R.D. Interhemispheric interaction during childhood: II. Children with early-treated phenylketonuria. Dev. Neuropsychol. 2000, 18:53-71.
13. Brumm V.L., Azen C., Moats R.A., Stern A.M., Broomand C., Nelson M.D., Koch R. Neuropsychological outcome of subjects participating in the PKU adult collaborative study: a preliminary review. J. Inherit. Metab. Dis. 2004, 27:549-566.
14. Chang P.N., Gray R.M., O'Brien L.L. Patterns of academic achievement among patients treated early with phenylketonuria 339. Eur. J. Pediatr. 2000, 159(Suppl 2):S96-S99.
15. Channon S., German E., Cassina C., Lee P. Executive functioning, memory, and learning in phenylketonuria. Neuropsychology 2004, 18:613-620.
16. Channon S., Mockler C., Lee P. Executive functioning and speed of processing in phenylketonuria. Neuropsychology 2005, 19:679-686.
17. Channon S., Goodman G., Zlotowitz S., Mockler C., Lee P.J. Effects of dietary management of phenylketonuria on long-term cognitive outcome. Arch. Dis. Child. 2007, 92:213-218.
18. Christ S.E., Steiner R.D., Grange D.K., Abrams R.A., White D.A. Inhibitory control in children with phenylketonuria. Dev. Neuropsychol. 2006, 30:845-864.
19. Christ S.E., Moffitt A.J., Peck D. Disruption of prefrontal function and connectivity in individuals with phenylketonuria. Mol. Genet. Metab. 2009, 99.
20. de Sonneville L.M.J., Huijbregts S.C.J., van Spronsen F.J., Verkerk P.H., Sergeant J.A., Licht R. Event-related potential correlates of selective processing in early- and continuously-treated children with phenylketonuria: effects of concurrent phenylalanine level and dietary control. Mol. Genet. Metab. 2009, 99.
21. DeRoche K., Welsh M. Twenty-five years of research on neurocognitive outcomes in early-treated phenylketonuria: intelligence and executive function. Dev. Neuropsychol. 2008, 33:474-504.
22. Feldmann R., Denecke J., Pietsch M., Grenzebach M., Weglage J. Phenylketonuria: no specific frontal lobe-dependent neuropsychological deficits of early-treated patients in comparison with diabetics. Pediatr. Res. 2002, 51:761-765.
23. Feldmann R., Denecke J., Grenzebach M., Weglage J. Frontal lobe-dependent functions in treated phenylketonuria: blood phenylalanine concentrations and long-term deficits in adolescents and young adults. J. Inherit. Metab. Dis. 2005, 28:445-455.
24. Gassio R., Vilaseca M.A., Lambruschini N., Boix C., Fuste M.E., Campistol J. Cognitive functions in patients with phenylketonuria in long-term treatment with tetrahydrobiopterin. Mol. Genet. Metab. 2009, 99.
25. Gassio R., Artuch R., Vilaseca M.A., Fuste E., Boix C., Sans A., Campistol J. Cognitive functions in classic phenylketonuria and mild hyperphenylalaninaemia: experience in a paediatric population. Dev. Med. Child Neurol. 2005, 47:443-448.
26. Gassio R., Fuste E., Lopez-Sala A., Artuch R., Vilaseca M.A., Campistol J. School performance in early and continuously treated phenylketonuria. Pediatr. Neurol. 2005, 33:267-271.
27. Griffiths P.V., Demellweek C., Fay N., Robinson P.H., Davidson D.C. Wechsler subscale IQ and subtest profile in early treated phenylketonuria. Arch. Dis. Child. 2000, 82:209-215.
28. Griffiths P., Robinson P., Davies R., Hayward K., Lewis K., Livingstone K., Plews S. Speed of decision-making and set-switching: subtle executive deficits in children with treated phenylketonuria. Educational and Child Psychology 2005, vol. 22(2):81-89.
29. Henderson R.M., McCulloch D.L., Herbert A.M., Robinson P.H., Taylor M.J. Visual event-related potentials in children with phenylketonuria. Acta Paediatr. 2000, 89:52-57.
30. Huijbregts S., de Sonneville L., Licht R., Sergeant J., van Spronsen F. Inhibition of prepotent responding and attentional flexibility in treated phenylketonuria. Dev. Neuropsychol. 2002, 22:481-499.
31. Huijbregts S.C., De Sonneville L.M., Licht R., van Spronsen F.J., Sergeant J.A. Short-term dietary interventions in children and adolescents with treated phenylketonuria: effects on neuropsychological outcome of a well-controlled population. J. Inherit. Metab. Dis. 2002, 25:419-430.
32. Huijbregts S.C., De Sonneville L.M., Licht R., van Spronsen F.J., Verkerk P.H., Sergeant J.A. Sustained attention and inhibition of cognitive interference in treated phenylketonuria: associations with concurrent and lifetime phenylalanine concentrations. Neuropsychologia 2002, 40:7-15.
33. Huijbregts S.C., De Sonneville L.M., van Spronsen F.J., Licht R., Sergeant J.A. The neuropsychological profile of early and continuously treated phenylketonuria: orienting, vigilance, and maintenance versus manipulation-functions of working memory. Neurosci. Biobehav. Rev. 2002, 26:697-712.
34. Huijbregts S.C., De Sonneville L.M., van Spronsen F.J., Berends I.E., Licht R., Verkerk P.H., Sergeant J.A. Motor function under lower and higher controlled processing demands in early and continuously treated phenylketonuria. Neuropsychology 2003, 17:369-379.
35. Jusiene R., Cimbalistiene L., Bieliauskaite R. Psychological adjustment of children with phenylketonuria. Medicina (Kaunas.) 2002, 38:424-430.
36. Jusiene R., Kucinskas V. Psychological adjustment of children with congenital hypothyroidism and phenylketonuria as related to parental psychological adjustment. Medicina (Kaunas.) 2004, 40:663-670.
37. Koch R., Burton B., Hoganson G., Peterson R., Rhead W., Rouse B., Scott R., Wolff J., Stern A.M., Guttler F., Nelson M., de la C.F., Coldwell J., Erbe R., Geraghty M.T., Shear C., Thomas J., Azen C. Phenylketonuria in adulthood: a collaborative study. J. Inherit. Metab. Dis. 2002, 25:333-346.
38. Koletzko B., Beblo S., Demmelmair H., Muller-Felber W., Hanebutt F.L. Does dietary DHA improve neural function in children? Observations in phenylketonuria. Prostaglandins Leukot. Essent. Fatty Acids 2009, 81:159-164.
39. Koletzko B., Beblo S., Demmelmair H., Hanebutt F.L. Omega-3 LC-PUFA supply and neurological outcomes in children with phenylketonuria (PKU). J. Pediatr. Gastroenterol. Nutr. 2009, 48(Suppl 1):S2-S7.
40. Landolt M.A., Nuoffer J.M., Steinmann B., Superti-Furga A. Quality of life and psychologic adjustment in children and adolescents with early treated phenylketonuria can be normal. J. Pediatr. 2002, 140:516-521.
41. Leuzzi V., Seri S., Cerquiglini A., Carducci C., Carducci C., Antonozzi I. Derangement of the dopaminergic system in phenylketonuria: study of the event-related potential (P300)349. J. Inherit. Metab. Dis. 2000, 23:317-320.
42. Leuzzi V., Pansini M., Sechi E., Chiarotti F., Carducci C., Levi G., Antonozzi I. Executive function impairment in early-treated PKU subjects with normal mental development. J. Inherit. Metab. Dis. 2004, 27:115-125.
43. Luciana M., Sullivan J., Nelson C.A. Associations between phenylalanine-to-tyrosine ratios and performance on tests of neuropsychological function in adolescents treated early and continuously for phenylketonuria. Child Dev. 2001, 72:1637-1652.
44. Luciana M., Hanson K.L., Whitley C.B. A preliminary report on dopamine system reactivity in PKU: acute effects of haloperidol on neuropsychological, physiological, and neuroendocrine functions. Psychopharmacology (Berl) 2004, 175:18-25.
45. Malloy-Diniz L.F., Cardoso-Martins C., Carneiro K.C., Cerqueira M.M., Ferreira A.P., Aguiar M.J., Starling A.L. Executive functions in children with phenylketonuria: variations as a function of phenilalanine plasm level. Arq. Neuropsiquiatr. 2004, 62:473-479.
46. Moyle J.J., Fox A.M., Bynevelt M., Arthur M., Burnett J.R. Event-related potentials elicited during a visual Go-Nogo task in adults with phenylketonuria. Clin. Neurophysiol. 2006, 117:2154-2160.
47. Moyle J.J., Fox A.M., Bynevelt M., Arthur M., Burnett J.R. A neuropsychological profile of off-diet adults with phenylketonuria. J. Clin. Exp. Neuropsychol. 2007, 29:436-441.
48. Moyle J.J., Fox A.M., Arthur M., Bynevelt M., Burnett J.R. Meta-analysis of neuropsychological symptoms of adolescents and adults with PKU. Neuropsychol. Rev. 2007, 17:91-101.
49. Rupp A., Kreis R., Zschocke J., Slotboom J., Boesch C., Rating D., Pietz J. Variability of blood-brain ratios of phenylalanine in typical patients with phenylketonuria. J. Cereb. Blood Flow Metab. 2001, 21:276-284.
50. Schindeler S., Ghosh-Jerath S., Thompson S., Rocca A., Joy P., Kemp A., Rae C., Green K., Wilcken B., Christodoulou J. The effects of large neutral amino acid supplements in PKU: an MRS and neuropsychological study. Mol. Genet. Metab. 2007, 91:48-54.
51. Sharman R., Sullivan K., Young R., McGill J. Biochemical markers associated with executive function in adolescents with early and continuously treated phenylketonuria. Clin. Genet. 2009, 75:169-174.
52. Simon E., Schwarz M., Roos J., Dragano N., Geraedts M., Siegrist J., Kamp G., Wendel U. Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU). Health Qual. Life Outcomes. 2008, 6:25.
53. Smith I., Knowles J. Behaviour in early treated phenylketonuria: a systematic review. Eur. J. Pediatr. 2000, 159(Suppl 2):S89-S93.
54. Smith M.L., Klim P., Hanley W.B. Hanley, Executive function in school-aged children with phenylketonuria. J. Dev. Phys. Disabil. Dec 2000, 12(4):317-332.
55. Stemerdink B.A., Kalverboer A.F., van der Meere J.J., van der Molen M.W., Huisman J., de Jong L.W., Slijper F.M., Verkerk P.H., van Spronsen F.J. Behaviour and school achievement in patients with early and continuously treated phenylketonuria. J. Inherit. Metab. Dis. 2000, 23:548-562.
56. VanZutphen K.H., Packman W., Sporri L., Needham M.C., Morgan C., Weisiger K., Packman S. Executive functioning in children and adolescents with phenylketonuria. Clin. Genet. 2007, 72:13-18.
57. Waisbren S.E., Noel K., Fahrbach K., Cella C., Frame D., Dorenbaum A., Levy H. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol. Genet. Metab. 2007, 92:63-70.
58. Weglage J., Grenzebach M., Pietsch M., Feldmann R., Linnenbank R., Denecke J., Koch H.G. Behavioural and emotional problems in early-treated adolescents with phenylketonuria in comparison with diabetic patients and healthy controls. J. Inherit. Metab. Dis. 2000, 23:487-496.
59. White D.A., Nortz M.J., Mandernach T., Huntington K., Steiner R.D. Deficits in memory strategy use related to prefrontal dysfunction during early development: evidence from children with phenylketonuria. Neuropsychology 2001, 15:221-229.
60. White D.A., Nortz M.J., Mandernach T., Huntington K., Steiner R.D. Age-related working memory impairments in children with prefrontal dysfunction associated with phenylketonuria. J. Int. Neuropsychol. Soc. 2002, 8:1-11.
61. Wiersema J.R., van der Meere J.J., Roeyers H. State regulation and response inhibition in children with ADHD and children with early- and continuously treated phenylketonuria: an event-related potential comparison. J. Inherit. Metab. Dis. 2005, 28:831-843.
62. Lundstedt G., Johansson A., Melin L., Alm J. Adjustment and intelligence among children with phenylketonuria in Sweden. Acta Paediatr. 2001, 90:1147-1152.
63. Sullivan J.E. Emotional outcome of adolescents and young adults with early and continuously treated phenylketonuria. J. Pediatr. Psychol. 2001, 26:477-484.
64. Bik-Multanowski M., Didycz B., Mozrzymas R., Nowacka M., Kaluzny L., Cichy W., Schneiberg B., Amilkiewicz J., Bilar A., Gizewska M., Lange A., Starostecka E., Chrobot A., Wojcicka-Bartlomiejczyk B.I., Milanowski A. Quality of life in noncompliant adults with phenylketonuria after resumption of the diet. J. Inherit. Metab. Dis. 2009, 32:126.
65. Gassio R., Campistol J., Vilaseca M.A., Lambruschini N., Cambra F.J., Fuste E. Do adult patients with phenylketonuria improve their quality of life after introduction/resumption of a phenylalanine-restricted diet?. Acta Paediatr. 2003, 92:1474-1478.
66. Bosch A.M., Tybout W., van Spronsen F.J., de Valk H.W., Wijburg F.A., Grootenhuis M.A. The course of life and quality of life of early and continuously treated Dutch patients with phenylketonuria. J. Inherit. Metab. Dis. 2007, 30:29-34.
67. Bosch A.M., Maurice-Stam H., Wijburg F.A., Grootenhuis M.A. Remarkable differences: the course of life of young adults with galactosaemia and PKU. J. Inherit. Metab. Dis. 2009, 32:706-712.
68. Christ S.E., Moffitt A.J., Peck D. Disruption of prefrontal function and connectivity in individuals with phenylketonuria. Mol. Genet. Metab. 2010, 99 Suppl 1. S33-40.
69. Dezortova M., Hajek M., Tintera J., Hejcmanova L., Sykova E. MR in phenylketonuria-related brain lesions. Acta Radiol. 2001, 42:459-466.
70. Ding X.Q., Fiehler J., Kohlschutter B., Wittkugel O., Grzyska U., Zeumer H., Ullrich K. MRI abnormalities in normal-appearing brain tissue of treated adult PKU patients. J. Magn. Reson. Imaging 2008, 27:998-1004.
71. He Q., Christ S.E., Karsch K., Moffitt A.J., Peck D., Duan Y. Detecting 3D Corpus Callosum abnormalities in phenylketonuria. Int. J. Comput. Biol. Drug Des. 2009, 2:289-301.
72. Hoeksma M., Reijngoud D.J., Pruim J., de Valk H.W., Paans A.M., van Spronsen F.J. Phenylketonuria: high plasma phenylalanine decreases cerebral protein synthesis 39. Mol. Genet. Metab. 2009, 96:177-182.
73. Izumi M., Yamazaki H., Nakabayashi H., Owada M. Magnetic resonance imaging of the brain in phenylketonuria. No To Hattatsu 2006, 38:27-31.
74. Koch R., Moats R., Guttler F., Guldberg P., Nelson M. Blood-brain phenylalanine relationships in persons with phenylketonuria. Pediatrics 2000, 106:1093-1096.
75. Kono K., Okano Y., Nakayama K., Hase Y., Minamikawa S., Ozawa N., Yokote H., Inoue Y. Diffusion-weighted MR imaging in patients with phenylketonuria: relationship between serum phenylalanine levels and ADC values in cerebral white matter. Radiology 2005, 236:630-636.
76. Landvogt C., Mengel E., Bartenstein P., Buchholz H.G., Schreckenberger M., Siessmeier T., Scheurich A., Feldmann R., Weglage J., Cumming P., Zepp F., Ullrich K. Reduced cerebral fluoro-L-dopamine uptake in adult patients suffering from phenylketonuria. J. Cereb. Blood Flow Metab. 2008, 28:824-831.
77. Leuzzi V., Bianchi M.C., Tosetti M., Carducci C.L., Carducci C.A., Antonozzi I. Clinical significance of brain phenylalanine concentration assessed by in vivo proton magnetic resonance spectroscopy in phenylketonuria. J. Inherit. Metab. Dis. 2000, 23:563-570.
78. Leuzzi V., Tosetti M., Montanaro D., Carducci C., Artiola C., Carducci C., Antonozzi I., Burroni M., Carnevale F., Chiarotti F., Popolizio T., Giannatempo G.M., D'Alesio V., Scarabino T. The pathogenesis of the white matter abnormalities in phenylketonuria. A multimodal 3.0 tesla MRI and magnetic resonance spectroscopy (1H MRS) study. J. Inherit. Metab. Dis. 2007, 30:209-216.
79. Manara R., Burlina A.P., Citton V., Ermani M., Vespignani F., Carollo C., Burlina A.B. Brain MRI diffusion-weighted imaging in patients with classical phenylketonuria. Neuroradiology 2009, 51:803-812.
80. Moats R.A., Koch R., Moseley K., Guldberg P., Guttler F., Boles R.G., Nelson M.D. Brain phenylalanine concentration in the management of adults with phenylketonuria. J. Inherit. Metab. Dis. 2000, 23:7-14.
81. Moller H.E., Weglage J., Bick U., Wiedermann D., Feldmann R., Ullrich K. Brain imaging and proton magnetic resonance spectroscopy in patients with phenylketonuria. Pediatrics 2003, 112:1580-1583.
82. Perez-Duenas B., Pujol J., Soriano-Mas C., Ortiz H., Artuch R., Vilaseca M.A., Campistol J. Global and regional volume changes in the brains of patients with phenylketonuria. Neurology 2006, 66:1074-1078.
83. Pfaendner N.H., Reuner G., Pietz J., Jost G., Rating D., Magnotta V.A., Mohr A., Kress B., Sartor K., Hahnel S. MR imaging-based volumetry in patients with early-treated phenylketonuria. AJNR Am. J. Neuroradiol. 2005, 26:1681-1685.
84. Pietz J., Rupp A., Ebinger F., Rating D., Mayatepek E., Boesch C., Kreis R. Cerebral energy metabolism in phenylketonuria: findings by quantitative In vivo 31P MR spectroscopy. Pediatr. Res. 2003, 53:654-662.
85. Scarabino T., Popolizio T., Tosetti M., Montanaro D., Giannatempo G.M., Terlizzi R., Pollice S., Maiorana A., Maggialetti N., Carriero A., Leuzzi V., Salvolini U. Phenylketonuria: white-matter changes assessed by 3.0-T magnetic resonance (MR) imaging, MR spectroscopy and MR diffusion. Radiol. Med. 2009, 114:461-474.
86. Schulpis K.H., Karikas G.A., Tjamouranis J., Michelakakis H., Tsakiris S. Acetylcholinesterase activity and biogenic amines in phenylketonuria250. Clin. Chem. 2002, 48:1794-1796.
87. Sirrs S.M., Laule C., Madler B., Brief E.E., Tahir S.A., Bishop C., MacKay A.L. Normal-appearing white matter in patients with phenylketonuria: water content, myelin water fraction, and metabolite concentrations. Radiology 2007, 242:236-243.
88. Vermathen P., Robert-Tissot L., Pietz J., Lutz T., Boesch C., Kreis R. Characterization of white matter alterations in phenylketonuria by magnetic resonance relaxometry and diffusion tensor imaging. Magn. Reson. Med. 2007, 58:1145-1156.
89. Wang Z.X., Zhou Z.S., Yu W.M. Brain white matter lesions of children with phenylketonuria before and after treatment. Zhongguo Dang Dai Er Ke Za Zhi 2006, 8:13-16.
90. Wasserstein M.P., Snyderman S.E., Sansaricq C., Buchsbaum M.S. Cerebral glucose metabolism in adults with early treated classic phenylketonuria. Mol. Genet. Metab. 2006, 87:272-277.
91. Weglage J., Wiedermann D., Denecke J., Feldmann R., Koch H.G., Ullrich K., Harms E., Moller H.E. Individual blood-brain barrier phenylalanine transport determines clinical outcome in phenylketonuria. Ann. Neurol. 2001, 50:463-467.
92. White D.A., Connor L.T., Nardos B., Shimony J.S., Archer R., Snyder A.Z., Moinuddin A., Grange D.K., Steiner R.D., McKinstry R.C. Age-related decline in the microstructural integrity of white matter in children with early- and continuously-treated PKU: a DTI study of the corpus callosum. Mol. Genet. Metab. 2009, 99.
93. Schulpis K.H., Kariyannis C., Papassotiriou I. Serum levels of neural protein S-100B in phenylketonuria 196. Clin. Biochem. 2004, 37:76-79.
94. Acosta P.B., Yannicelli S., Singh R., Mofidi S., Steiner R., DeVincentis E., Jurecki E., Bernstein L., Gleason S., Chetty M., Rouse B. Nutrient intakes and physical growth of children with phenylketonuria undergoing nutrition therapy. J. Am. Diet. Assoc. 2003, 103:1167-1173.
95. Acosta P.B., Yannicelli S., Singh R.H., Elsas L.J., Mofidi S., Steiner R.D. Iron status of children with phenylketonuria undergoing nutrition therapy assessed by transferrin receptors. Genet. Med. 2004, 6:96-101.
96. Agostoni C., Harvie A., McCulloch D.L., Demellweek C., Cockburn F., Giovannini M., Murray G., Harkness R.A., Riva E. A randomized trial of long-chain polyunsaturated fatty acid supplementation in infants with phenylketonuria. Dev. Med. Child Neurol. 2006, 48:207-212.
97. Arnold G.L., Kirby R., Preston C., Blakely E. Iron and protein sufficiency and red cell indices in phenylketonuria. J. Am. Coll. Nutr. 2001, 20:65-70.
98. Arnold G.L., Vladutiu C.J., Kirby R.S., Blakely E.M., Deluca J.M. Protein insufficiency and linear growth restriction in phenylketonuria. J. Pediatr. 2002, 141:243-246.
99. Beblo S., Reinhardt H., Muntau A.C., Mueller-Felber W., Roscher A.A., Koletzko B. Fish oil supplementation improves visual evoked potentials in children with phenylketonuria. Neurology 2001, 57:1488-1491.
100. Beblo S., Reinhardt H., Demmelmair H., Muntau A.C., Koletzko B. Effect of fish oil supplementation on fatty acid status, coordination, and fine motor skills in children with phenylketonuria. J. Pediatr. 2007, 150:479-484.
101. Cleary M.A., Feillet F., White F.J., Vidailhet M., MacDonald A., Grimsley A., Maurin N., de Baulny H.O., Rutherford P.J. Randomised controlled trial of essential fatty acid supplementation in phenylketonuria. Eur. J. Clin. Nutr. 2006, 60:915-920.
102. Colome C., Artuch R., Vilaseca M.A., Sierra C., Brandi N., Lambruschini N., Cambra F.J., Campistol J. Lipophilic antioxidants in patients with phenylketonuria247. Am. J. Clin. Nutr. 2003, 77:185-188.
103. Dobbelaere D., Michaud L., Debrabander A., Vanderbecken S., Gottrand F., Turck D., Farriaux J.P. Evaluation of nutritional status and pathophysiology of growth retardation in patients with phenylketonuria. J. Inherit. Metab. Dis. 2003, 26:1-11.
104. Gassio R., Artuch R., Vilaseca M.A., Fuste E., Colome R., Campistol J. Cognitive functions and the antioxidant system in phenylketonuric patients. Neuropsychology 2008, 22:426-431.
105. Hoeksma M., van Rijn M., Verkerk P.H., Bosch A.M., Mulder M.F., de Klerk J.B., de Koning T.J., Rubio-Gozalbo E., de Vries M., Sauer P.J., van Spronsen F.J. The intake of total protein, natural protein and protein substitute and growth of height and head circumference in Dutch infants with phenylketonuria. J. Inherit. Metab. Dis. 2005, 28:845-854.
106. Huemer M., Fodinger M., Bodamer O.A., Muhl A., Herle M., Weigmann C., Ulmer H., Stockler-Ipsiroglu S., Moslinger D. Total homocysteine, B-vitamins and genetic polymorphisms in patients with classical phenylketonuria. Mol. Genet. Metab. 2008, 94:46-51.
107. Hvas A.M., Nexo E., Nielsen J.B. Vitamin B12 and vitamin B6 supplementation is needed among adults with phenylketonuria (PKU). J. Inherit. Metab. Dis. 2006, 29:47-53.
108. Koletzko B., Sauerwald T., Demmelmair H., Herzog M., von Schenck U., Bohles H., Wendel U., Seidel J. Dietary long-chain polyunsaturated fatty acid supplementation in infants with phenylketonuria: a randomized controlled trial. J. Inherit. Metab. Dis. 2007, 30:326-332.
109. Lucock M., Yates Z., Hall K., Leeming R., Rylance G., MacDonald A., Green A. The impact of phenylketonuria on folate metabolism 254. Mol. Genet. Metab. 2002, 76:305-312.
110. Macleod E.L., Gleason S.T., van Calcar S.C., Ney D.M. Reassessment of phenylalanine tolerance in adults with phenylketonuria is needed as body mass changes. Mol. Genet. Metab. 2009, 98:331-337.
111. Moseley K., Koch R., Moser A.B. Lipid status and long-chain polyunsaturated fatty acid concentrations in adults and adolescents with phenylketonuria on phenylalanine-restricted diet. J. Inherit. Metab. Dis. 2002, 25:56-64.
112. Ormazabal A., Vilaseca M.A., Perez-Duenas B., Lambruschini N., Gomez L., Campistol J., Artuch R. Platelet serotonin concentrations in PKU patients under dietary control and tetrahydrobiopterin treatment 710. J. Inherit. Metab. Dis. 2005, 28:863-870.
113. Robinson M., White F.J., Cleary M.A., Wraith E., Lam W.K., Walter J.H. Increased risk of vitamin B12 deficiency in patients with phenylketonuria on an unrestricted or relaxed diet. J. Pediatr. 2000, 136:545-547.
114. Rose H.J., White F., MacDonald A., Rutherford P.J., Favre E. Fat intakes of children with PKU on low phenylalanine diets. J. Hum. Nutr. Diet. 2005, 18:395-400.
115. Schulpis K.H., Karikas G.A., Papakonstantinou E. Homocysteine and other vascular risk factors in patients with phenylketonuria on a diet. Acta Paediatr. 2002, 91:905-909.
116. Schulpis K.H., Tsakiris S., Traeger-Synodinos J., Papassotiriou I. Low total antioxidant status is implicated with high 8-hydroxy-2-deoxyguanosine serum concentrations in phenylketonuria 154. Clin. Biochem. 2005, 38:239-242.
117. Schulpis K.H., Papassotiriou I., Tsakiris S., Vounatsou M., Chrousos G.P. Increased plasma adiponectin concentrations in poorly controlled patients with phenylketonuria normalize with a strict diet: evidence for catecholamine-mediated adiponectin regulation and a complex effect of phenylketonuria diet on atherogenesis risk factors 141. Metabolism 2005, 54:1350-1355.
118. Sirtori L.R., Dutra-Filho C.S., Fitarelli D., Sitta A., Haeser A., Barschak A.G., Wajner M., Coelho D.M., Llesuy S., Bello-Klein A., Giugliani R., Deon M., Vargas C.R. Oxidative stress in patients with phenylketonuria 151. Biochim. Biophys. Acta 2005, 1740:68-73.
119. van Gool C.J., van Houwelingen A.C., Hornstra G. The essential fatty acid status in phenylketonuria patients under treatment. J. Nutr. Biochem. 2000, 11:543-547.
120. Weigel C., Kiener C., Meier N., Schmid P., Rauh M., Rascher W., Knerr I. Carnitine status in early-treated children, adolescents and young adults with phenylketonuria on low phenylalanine diets 43. Ann. Nutr. Metab. 2008, 53:91-95.
121. Acosta P.B., Yannicelli S., Singh R., Eisas L.J., Kennedy M.J., Bernstein L., Rohr F., Trahms C., Koch R., Breck J. Intake and blood levels of fatty acids in treated patients with phenylketonuria. J. Pediatr. Gastroenterol. Nutr. 2001, 33:253-259.
122. Colome C., Artuch R., Sierra C., Brandi N., Lambruschini N., Campistol J., Vilaseca M.A. Plasma thiols and their determinants in phenylketonuria. Eur. J. Clin. Nutr. 2003, 57:964-968.
123. Huemer M., Huemer C., Moslinger D., Huter D., Stockler-Ipsiroglu S. Growth and body composition in children with classical phenylketonuria: results in 34 patients and review of the literature. J. Inherit. Metab. Dis. 2007, 30:694-699.
124. Lavoie S.M., Harding C.O., Gillingham M.B. Normal fatty acid concentrations in young children with phenylketonuria (PKU). Top. Clin. Nutr. 2009, 24:333-340.
125. van Rijn M., Hoeksma M., Sauer P., Szczerbak B., Gross M., Reijngoud D.J., van Spronsen F. Protein metabolism in adult patients with phenylketonuria 89. Nutrition 2007, 23:445-453.
126. Ambroszkiewicz J., Gajewska J., Laskowska-Klita T. Markers of bone formation and resorption in prepubertal children with phenylketonuria. Med. Wieku. Rozwoj. 2003, 7:89-95.
127. Ambroszkiewicz J., Gajewska J., Chelchowska M., Oltarzewski M., Laskowska-Klita T., Nowacka M., Milanowski A. Concentration of osteoprotegerin, bone formation and resorption markers in patients with phenylketonuria. Pol. Merkur Lekarski. 2008, 25:57-60.
128. Barat P., Barthe N., Redonnet-Vernhet I., Parrot F. The impact of the control of serum phenylalanine levels on osteopenia in patients with phenylketonuria244. Eur. J. Pediatr. 2002, 161:687-688.
129. V.S. Lucas, A. Contreras, M. Loukissa, G.J. Roberts, Dental disease indices and caries related oral microflora in children with phenylketonuria 275. ASDC J. Dent. Child 68 (2001) 263-7, 229.
130. Millet P., Vilaseca M.A., Valls C., Perez-Duenas B., Artuch R., Gomez L., Lambruschini N., Campistol J. Is deoxypyridinoline a good resorption marker to detect osteopenia in phenylketonuria?. Clin. Biochem. 2005, 38:1127-1132.
131. Modan-Moses D., Vered I., Schwartz G., Anikster Y., Abraham S., Segev R., Efrati O. Peak bone mass in patients with phenylketonuria. J. Inherit. Metab. Dis. 2007, 30:202-208.
132. Porta F., Roato I., Mussa A., Repici M., Gorassini E., Spada M., Ferracini R. Increased spontaneous osteoclastogenesis from peripheral blood mononuclear cells in phenylketonuria. J. Inherit. Metab. Dis. 2008, 10.1007/s10545-008-0907-9.
133. Porta F., Spada M., Lala R., Mussa A. Phalangeal quantitative ultrasound in children with phenylketonuria: a pilot study. Ultrasound Med. Biol. 2008, 34:1049-1052.
134. Perez-Duenas B., Cambra F.J., Vilaseca M.A., Lambruschini N., Campistol J., Camacho J.A. New approach to osteopenia in phenylketonuric patients. Acta Paediatr. 2002, 91:899-904.
135. Acosta P.B., Matalon K., Castiglioni L., Rohr F.J., Wenz E., Austin V., Azen C. Intake of major nutrients by women in the Maternal Phenylketonuria (MPKU) Study and effects on plasma phenylalanine concentrations. Am. J. Clin. Nutr. 2001, 73:792-796.
136. Brown A.S., Fernhoff P.M., Waisbren S.E., Frazier D.M., Singh R., Rohr F., Morris J.M., Kenneson A., MacDonald P., Gwinn M., Honein M., Rasmussen S.A. Barriers to successful dietary control among pregnant women with phenylketonuria. Genet. Med. 2002, 4:84-89.
137. Feillet F., Abadie V., Berthelot J., Maurin N., Ogier H., Vidailhet M., Farriaux J.P., de Parscau L. Maternal phenylketonuria: the French survey. Eur. J. Pediatr. 2004, 163:540-546.
138. Hanley W.B., Azen C., Koch R., Michals-Matalon K., Matalon R., Rouse B., Trefz F., Waisbren S., de la C.F. Maternal phenylketonuria collaborative study (MPKUCS) the 'outliers'. J. Inherit. Metab. Dis. 2004, 27:711-723.
139. Koch R., Hanley W., Levy H., Matalon K., Matalon R., Rouse B., Trefz F., Guttler F., Azen C., Platt L., Waisbren S., Widaman K., Ning J., Friedman E.G., de la C.F. The Maternal Phenylketonuria International Study: 1984-2002. Pediatrics 2003, 112:1523-1529.
140. Lee P.J., Lilburn M., Baudin J. Maternal phenylketonuria: experiences from the United Kingdom. Pediatrics 2003, 112:1553-1556.
141. Lee P.J., Ridout D., Walter J.H., Cockburn F. Maternal phenylketonuria: report from the United Kingdom Registry 1978-97. Arch. Dis. Child. 2005, 90:143-146.
142. Levy H.L., Guldberg P., Guttler F., Hanley W.B., Matalon R., Rouse B.M., Trefz F., Azen C., Allred E.N., de la C.F., Koch R. Congenital heart disease in maternal phenylketonuria: report from the Maternal PKU Collaborative Study. Pediatr. Res. 2001, 49:636-642.
143. Magee A.C., Ryan K., Moore A., Trimble E.R. Follow up of fetal outcome in cases of maternal phenylketonuria in Northern Ireland. Arch. Dis. Child. Fetal Neonatal Ed. 2002, 87:F141-F143.
144. Maillot F., Lilburn M., Baudin J., Morley D.W., Lee P.J. Factors influencing outcomes in the offspring of mothers with phenylketonuria during pregnancy: the importance of variation in maternal blood phenylalanine. Am. J. Clin. Nutr. 2008, 88:700-705.
145. Matalon K.M., Acosta P.B., Azen C. Role of nutrition in pregnancy with phenylketonuria and birth defects. Pediatrics 2003, 112:1534-1536.
146. Michals-Matalon K., Platt L.D., Acosta P.P., Azen C., Walla C.A. Nutrient intake and congenital heart defects in maternal phenylketonuria. Am. J. Obstet. Gynecol. 2002, 187:441-444.
147. Ng T.W., Rae A., Wright H., Gurry D., Wray J. Maternal phenylketonuria in Western Australia: pregnancy outcomes and developmental outcomes in offspring. J. Paediatr. Child Health 2003, 39:358-363.
148. Platt L.D., Koch R., Hanley W.B., Levy H.L., Matalon R., Rouse B., Trefz F., de la C.F., Guttler F., Azen C., Friedman E.G. The international study of pregnancy outcome in women with maternal phenylketonuria: report of a 12-year study. Am. J. Obstet. Gynecol. 2000, 182:326-333.
149. Rohr F., Munier A., Sullivan D., Bailey I., Gennaccaro M., Levy H., Brereton H., Gleason S., Goss B., Lesperance E., Moseley K., Singh R., Tonyes L., Vespa H., Waisbren S. The resource mothers study of maternal phenylketonuria: preliminary findings. J. Inherit. Metab. Dis. 2004, 27:145-155.
150. Rouse B., Matalon R., Koch R., Azen C., Levy H., Hanley W., Trefz F., de la C.F. Maternal phenylketonuria syndrome: congenital heart defects, microcephaly, and developmental outcomes. J. Pediatr. 2000, 136:57-61.
151. Waisbren S.E., Hanley W., Levy H.L., Shifrin H., Allred E., Azen C., Chang P.N., Cipcic-Schmidt S., de la C.F., Hall R., Matalon R., Nanson J., Rouse B., Trefz F., Koch R. Outcome at age 4 years in offspring of women with maternal phenylketonuria: the Maternal PKU Collaborative Study. JAMA 2000, 283:756-762.
152. Waisbren S.E., Azen C. Cognitive and behavioral development in maternal phenylketonuria offspring. Pediatrics 2003, 112:1544-1547.
153. Widaman K.F., Azen C. Relation of prenatal phenylalanine exposure to infant and childhood cognitive outcomes: results from the International Maternal PKU Collaborative Study. Pediatrics 2003, 112:1537-1543.
154. Blau N., Belanger-Quintana A., Demirkol M., Feillet F., Giovannini M., MacDonald A., Trefz F.K., van Spronsen F. Management of phenylketonuria in Europe: survey results from 19 countries. Mol. Genet. Metab. 2010, 99:109-115.
155. Ahring K., Belanger-Quintana A., Dokoupil K., Gokmen O.H., Lammardo A.M., MacDonald A., Motzfeldt K., Nowacka M., Robert M., van Rijn M. Dietary management practices in phenylketonuria across European centres. Clin. Nutr. 2009, 28:231-236.
156. van Spronsen F.J., Ahring K.K., Gizewska M. PKU-what is daily practice in various centres in Europe? Data from a questionnaire by the scientific advisory committee of the European Society of Phenylketonuria and Allied Disorders. J. Inherit. Metab. Dis. 2009, 32:58-64.
157. Shekelle P.G., Ortiz E., Rhodes S., Morton S.C., Eccles M.P., Grimshaw J.M., Woolf S.H. Validity of the Agency for Healthcare Research and Quality clinical practice guidelines: how quickly do guidelines become outdated?. JAMA 2001, 286:1461-1467.
158. Shekelle P., Eccles M.P., Grimshaw J.M., Woolf S.H. When should clinical guidelines be updated?. BMJ 2001, 323:155-157.
159. Walter J.H., White F.J., Hall S.K., MacDonald A., Rylance G., Boneh A., Francis D.E., Shortland G.J., Schmidt M., Vail A. How practical are recommendations for dietary control in phenylketonuria?. Lancet 2002, 360:55-57.
160. van Spronsen F.J., Burgard P. The truth of treating patients with phenylketonuria after childhood: the need for a new guideline. J. Inherit. Metab. Dis. 2008, 31:673-679.
161. Bilginsoy C., Waitzman N., Leonard C.O., Ernst S.L. Living with phenylketonuria: perspectives of patients and their families. J. Inherit. Metab. Dis. 2005, 28:639-649.
162. Peterson K., Slover R., Gass S., Seltzer W.K., McCabe L.L., McCabe E.R. Blood phenylalanine estimation for the patient with phenylketonuria using a portable device. Biochem. Med. Metab. Biol. 1988, 39:98-104.
163. Wang Z., Chen Y.Z., Zhang S., Zhou Z. Investigation of a phenylalanine-biosensor system for phenylketonuria detection. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2005, 2:1913-1916.
164. Musson D.G., Kramer W.G., Foehr E.D., Bieberdorf F.A., Hornfeldt C.S., Kim S.S., Dorenbaum A. Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food: a randomized, open-label, crossover study in healthy adults. Clin. Ther. 2010, 32:338-346.
165. Trefz F.K., Scheible D., Frauendienst-Egger G. Long-term follow-up of patients with phenylketonuria receiving tetrahydrobiopterin treatment. J. Inherit. Metab. Dis. 2010, 10.1007/s10545-010-9058-x.
166. van Spronsen F.J., Enns G.M. Future treatment strategies in phenylketonuria. Mol. Genet. Metab. 2010, 99(Suppl 1):S90-S95.
167. Blau N., Belanger-Quintana A., Demirkol M., Feillet F., Giovannini M., MacDonald A., Trefz F.K., van Spronsen F.J. Optimizing the use of sapropterin (BH(4)) in the management of phenylketonuria. Mol. Genet. Metab. 2009, 96:158-163.
168. Trefz F.K., Scheible D., Gotz H., Frauendienst-Egger G. Significance of genotype in tetrahydrobiopterin-responsive phenylketonuria. J. Inherit. Metab. Dis. 2009, 32:22-26.
169. Trefz F.K., Burton B.K., Longo N., Casanova M.M., Gruskin D.J., Dorenbaum A., Kakkis E.D., Crombez E.A., Grange D.K., Harmatz P., Lipson M.H., Milanowski A., Randolph L.M., Vockley J., Whitley C.B., Wolff J.A., Bebchuk J., Christ-Schmidt H., Hennermann J.B. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J. Pediatr. 2009, 154:700-707.
170. Lee P., Treacy E.P., Crombez E., Wasserstein M., Waber L., Wolff J., Wendel U., Dorenbaum A., Bebchuk J., Christ-Schmidt H., Seashore M., Giovannini M., Burton B.K., Morris A.A. Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria. Am. J. Med. Genet. A 2008, 146A:2851-2859.
171. Thompson C.A. First drug approved for treatment of phenylketonuria. Am. J. Health Syst. Pharm. 2008, 65:100.
172. Burton B.K., Grange D.K., Milanowski A., Vockley G., Feillet F., Crombez E.A., Abadie V., Harding C.O., Cederbaum S., Dobbelaere D., Smith A., Dorenbaum A. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study. J. Inherit. Metab. Dis. 2007, 30:700-707.
173. Levy H., Burton B., Cederbaum S., Scriver C. Recommendations for evaluation of responsiveness to tetrahydrobiopterin (BH(4)) in phenylketonuria and its use in treatment. Mol. Genet. Metab. 2007, 92:287-291.
174. Levy H.L., Milanowski A., Chakrapani A., Cleary M., Lee P., Trefz F.K., Whitley C.B., Feillet F., Feigenbaum A.S., Bebchuk J.D., Christ-Schmidt H., Dorenbaum A. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet 2007, 370:504-510.
175. Matalon R., Michals-Matalon K., Bhatia G., Burlina A.B., Burlina A.P., Braga C., Fiori L., Giovannini M., Grechanina E., Novikov P., Grady J., Tyring S.K., Guttler F. Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine. J. Inherit. Metab. Dis. 2007, 30:153-158.
176. Matalon R., Surendran S., Matalon K.M., Tyring S., Quast M., Jinga W., Ezell E., Szucs S. Future role of large neutral amino acids in transport of phenylalanine into the brain. Pediatrics 2003, 112:1570-1574.
177. Pietz J., Kreis R., Rupp A., Mayatepek E., Rating D., Boesch C., Bremer H.J. Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J. Clin. Invest 1999, 103:1169-1178.
178. Fiege B., Blau N. Assessment of tetrahydrobiopterin (BH4) responsiveness in phenylketonuria. J. Pediatr. 2007, 150:627-630.
179. Torres E.A. The NIH 2002 Consensus Conference on hepatitis C: what it said and what it means. P. R. Health Sci. J. 2004, 23:7-9.
180. Anon. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens. State Sci. Statements 2002, 19:1-46.
181. Anon. NIH consensus development conference targets prevention and management of hepatitis C. Am. Fam. Physician 1997, 56:959-961.
182. Marwick C. Hepatitis C is focus of NIH consensus panel. JAMA 1997, 277:1268-1269.